CZ20032540A3 - Synergické kombinace ligandů retinoidního receptoru a vybraných cytotoxických prostředků pro léčení rakoviny - Google Patents

Synergické kombinace ligandů retinoidního receptoru a vybraných cytotoxických prostředků pro léčení rakoviny Download PDF

Info

Publication number
CZ20032540A3
CZ20032540A3 CZ20032540A CZ20032540A CZ20032540A3 CZ 20032540 A3 CZ20032540 A3 CZ 20032540A3 CZ 20032540 A CZ20032540 A CZ 20032540A CZ 20032540 A CZ20032540 A CZ 20032540A CZ 20032540 A3 CZ20032540 A3 CZ 20032540A3
Authority
CZ
Czechia
Prior art keywords
rar
formula
cytotoxic agent
selected cytotoxic
paclitaxel
Prior art date
Application number
CZ20032540A
Other languages
Czech (cs)
English (en)
Inventor
Vivat@Hannahávalérieásandrine
Lorenziámatthewáv
Gottardisámarcoám
Zusiáfredáchristopher
Original Assignee
Bristol@Myersásquibbácompany
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol@Myersásquibbácompany filed Critical Bristol@Myersásquibbácompany
Publication of CZ20032540A3 publication Critical patent/CZ20032540A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CZ20032540A 2001-03-22 2002-03-22 Synergické kombinace ligandů retinoidního receptoru a vybraných cytotoxických prostředků pro léčení rakoviny CZ20032540A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27775401P 2001-03-22 2001-03-22

Publications (1)

Publication Number Publication Date
CZ20032540A3 true CZ20032540A3 (cs) 2004-05-12

Family

ID=23062213

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20032540A CZ20032540A3 (cs) 2001-03-22 2002-03-22 Synergické kombinace ligandů retinoidního receptoru a vybraných cytotoxických prostředků pro léčení rakoviny

Country Status (15)

Country Link
EP (1) EP1383491A2 (pl)
JP (1) JP2004528316A (pl)
KR (1) KR20030086314A (pl)
CN (1) CN1498105A (pl)
BR (1) BR0207681A (pl)
CA (1) CA2441335A1 (pl)
CZ (1) CZ20032540A3 (pl)
DE (1) DE02733871T1 (pl)
ES (1) ES2214985T1 (pl)
HU (1) HUP0400255A2 (pl)
IL (1) IL157358A0 (pl)
MX (1) MXPA03008403A (pl)
PL (1) PL368946A1 (pl)
TR (1) TR200400812T3 (pl)
WO (1) WO2002078620A2 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5113038B2 (ja) * 2006-03-23 2013-01-09 テムリック株式会社 癌治療用キットおよび癌治療用医薬組成物

Also Published As

Publication number Publication date
PL368946A1 (pl) 2005-04-04
KR20030086314A (ko) 2003-11-07
JP2004528316A (ja) 2004-09-16
HUP0400255A2 (hu) 2004-08-30
TR200400812T3 (tr) 2004-07-21
EP1383491A2 (en) 2004-01-28
CN1498105A (zh) 2004-05-19
IL157358A0 (en) 2004-02-19
DE02733871T1 (de) 2004-08-26
CA2441335A1 (en) 2002-10-10
MXPA03008403A (es) 2004-01-29
BR0207681A (pt) 2004-07-27
ES2214985T1 (es) 2004-10-01
WO2002078620A2 (en) 2002-10-10
WO2002078620A3 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
Kou et al. Arctigenin inhibits lipopolysaccharide-induced iNOS expression in RAW264. 7 cells through suppressing JAK-STAT signal pathway
Heller et al. Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo
Tang et al. Piceatannol inhibits the IL-1β-induced inflammatory response in human osteoarthritic chondrocytes and ameliorates osteoarthritis in mice by activating Nrf2
JPH09507050A (ja) 抗新生物剤としての酪酸、酪酸塩、および誘導体の生理学的に安定な組成物
CN110507655B (zh) 化合物fg-4592在制备治疗甲状腺激素受体介导疾病的药物制剂中的应用
US20060084704A1 (en) Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
Nagpal et al. Retinoids as anti-cancer agents
Jin et al. Acacetin inhibits RANKL-induced osteoclastogenesis and LPS-induced bone loss by modulating NFATc1 transcription
WO2021046497A3 (en) Orally delivered therapeutical composition and use thereof
US20040122080A1 (en) Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
EP1173061A1 (en) Compositions and methods for treatment of hyperproliferative diseases
US20250375468A1 (en) Novel ras inhibitors
MXPA06008520A (es) Realce de la actividad anti-androgenica por una combinacion de los inhibidores que apuntan diversos pasos de un camino esteroide-dependiente de la activacion del gen y su aplicacion.
JP2026508161A (ja) 新規RAS阻害剤3aH-シクロペンタ[b]ベンゾフラン-3a-イル
EP1383491A2 (en) Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
EP4536648A1 (en) Novel ras inhibitors
EP3707127B1 (en) COMPOUNDS FOR INHIBITING LY6K AND THEIR METHODS OF USE
AU2002305072A1 (en) Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
EP1804806A2 (en) Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
JP4904498B2 (ja) Rar活性化を起こす天然化合物
KR20140129616A (ko) 골 형성 과정에서 인간 작은 류신 지퍼 단백질의 용도
Mathisen et al. Delayed translocation of NGFI–B/RXR in glutamate stimulated neurons allows late protection by 9-cis retinoic acid
WO2024156704A1 (en) Novel mixtures as ras inhibitors for use in the treatment of proliferative and genetic diseases
WO2022185742A1 (ja) 播種性血管内凝固症候群の予防又は治療用組成物
CN118593523A (zh) 积雪草苷在制备治疗嘧霉胺中毒药物中的应用